Devita, Hellman, and Rosenberg's Cancer

LWBK1006-33 LWW-Govindan-Review November 24, 2011 11:25

460 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

Question 33.4. Which of the following is correct regarding the IPSS for MDS?

A. IPSS does not distinguish patients with moderate or severe cytopenias.

B. IPSS includes patients with 21% to 30% blasts in the bone marrow.

C. Normal cytogenetics are assigned an intermediate risk score.

D. All of the above.

Question 33.5. Which of the following genes is frequently mutated in patients with

therapy-related MDS?

A. AML/RUNX1

B. JAK2

C. c-kit

D. All of the above

Question 33.6. Which of the following statements is correct regarding therapy-related

MDS resulting from prior treatment with alkylating agents?

A. MDS occurs within the first 2 years after treatment with alkylating

agents.

B. Therapy-related MDS carries a good prognosis.

C. 90% of patients have aberrations of chromosomes 5 and/or 7.

D. All of the above.

Question 33.7. Which of the following has been implicated in the development of MDS?

A. Defective growth of stromal progenitors

B. Decreased mitochondrial cytochrome c mediated activation of

caspase-9

C. Decreased expression of Fas and Fas ligand

D. Decreased TNF--mediated signaling

Question 33.8. Which of the following is correct regarding the role of allogeneic

hematopoietic stem cell transplantation (HSCT) in MDS?

A. High-dose chemotherapy and allogeneic HSCT are the only known

curative therapy for patients with MDS.

B. Allogeneic HSCT is indicated at the time of presentation, in patients

with high-risk MDS, who have a matched sibling donor.

C. In pediatric MDS, diepoxybutane test must be performed prior to

transplant.

D. All of the above.